Qui, Xiangguo - University of Manitoba - Department of Medical Microbiology and Infectious Diseases

研究领域

Study emerging/re-emerging biosafety level (BSL) 3 and 4 viruses. My main interests are: to develop and test novel vaccine platforms for different applications including the protection against emerging pathogens; to develop and evaluate therapeutics especially mAb therapy for BSL3 and 4 viruses; to develop animal models as a tool for studying pathogenesis and identifying immune correlates of these viruses.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wong G, Richardson J, Cutts T, Qiu X and Kobinger GP. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Res. 2015 Jan 14;116C:17-19. doi: 10.1016/j.antiviral.2015.01.001. [Epub ahead of print] Chowell D, Castillo-Chavez C, Krishna S, Qiu X and Anderson KS. Predicting the impact of detecting pre-symptomatic Ebola infections on the transmission dynamics of the 2014 West African outbreak. The Lancet Infectious Disease Vol 15 February 2015 Choi JH, Jonsson-Schmmunk K, Qiu X, Shedlock D, et al. A Single Dose Mucosal Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Molecular Pharmaceutics. 2014 Nov 1. [Epub ahead of print] DOI: 10.1021/mp500646d Wong G, Qiu X, Richardson J, Cutts T, et al. Ebola virus transmission in guinea pigs. J Virol. 2014 Nov 12. pii: JVI.02836-14. [Epub ahead of print] Murin DM, Fusco ML, Bornholdt ZA, Qiu X, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus.. Proc Natl Acad Sci U S A. 2014 Nov 17. pii: 201414164. [Epub ahead of print] Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger GP and Qiu X. Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. Sci Rep. 2014 Nov 6; 4:6881. doi: 10.1038/srep06881. Wiliams K, Qiu X, Fernando L, Steven JM and Alimonti J. VSV?G/EBOV GP-induced Innate Protection Enhances NK Cell Activity to Increase Survival in a Lethal MA-EBOV Infection. Viral Immunol. 2014 Dec 10. [Epub ahead of print] de La Vega M, Wong G, Kobinger GK and Qiu X. The Multiple Roles of sGP in Ebola Pathogenesis. Viral Immunol. 2014 Oct 29. [Epub ahead of print] Qiu X, Wong G, et al Reversion of advanced Ebola virus disease in nonhuman primates treated with ZMappTM. Nature. 2014 Aug 29. doi:10.1038/nature13777. [Epub ahead of print] Wong G, Audet J, Fernando L, Fauster-Bovendo H, Alimonti JB, Kobinger GP and Qiu X. Immunization with vesicular stomatitis vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 32 (2014) 5722-5729 Qiu X, Wong G, Audet J, Cutts T, Niu Y, Booth S and Kobinger GP. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J Virol. 2014 Aug 20. pii: J Virol .01643-14. [Epub ahead of print] Alimonti J. B., Leung A., Jones S., Gren J., Qiu X., Fernando L., Balcewich B., Wong G., Str?her U., Grolla A., Strong J. E., and Kobinger G. P. (2014). Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Sci Rep. 2014 Jul 25;4:5824. doi: 10.1038/srep05824. Wong G, Kobinger GP, Qiu X. Characterization of immune response of Ebola virus infection. Expert Review of Clinical Immunology. 2014 Expert Rev Clin Immunol. 2014 Apr 18. [Epub ahead of print] Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections with monoclonal antibodies. Trends in Microbiol. 2014 Apr 30. pii: S0966-842X(14)00073-0. doi: 10.1016/j.tim.2014.04.002. [Epub ahead of print] Qiu X, Kobinger GP. Antibody therapy for Ebola: is the tide turning around? Human Vaccines & Immunotherapeutics. 2014; 10(4): . Lennemann NJ, Rhein BA, Chandran K, Qiu X and Maury W. Comprehensive functional analysis of N-linked glycans on the Ebola virus GP1. mBio 2014, Jan 28;5(1). pii: e00862-13. doi: 10.1128/mBio.00862-13. Qiu X, Kobinger GP. Retrospective Studies: an excellent tool to complement surveillance. JID 2013; doi: 10.1093/infdis/jit604 Qiu X, Audet J, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with monoclonal antibodies. Sci Rep 2013; 3:3365 doi: 10.1038/srep03365 Qiu X, Wong G, et al. MAbs and Ad-vectored IFN-á therapy rescues Ebola infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013, 5(207ra143) DOI: 10.1126/scitranslmed.3006605 Qiu X, Wong G, et al. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. J. Virol. 2013, 87(13):7754. DOI: 10.1128/JVI.00173-13. Wang G, Richardson JS, Pillet S, Patel A, Qiu X, et al. Immune Parameters Correlating with Protection against Ebola Virus Infection in Rodents and Nonhuman Primates. Sci Transl Med 2012, 31;4(158):158ra146. doi: 10.1126/scitranslmed.3004582. Qiu X, Audet J, et al. Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies. Sci Transl Med 2012, 4(138 ra81) DOI: 10.1126/scitranslmed.3003876 Qiu X, Fernando L, et al. Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection. PLoS Negl Trop Dis 2012; 6(3): e1575. doi:10.1371/journal.pntd.0001575 Qiu X, Fernando L, et al. Protective Immunodominant Zaire Ebolavirus Glycoprotein Epitope in Mice. J Bioterr Biodef 2011, S1, 006 Qiu X, Alimonti JB, et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 2011, 141, 218-227 Qiu X, Fernando L, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009; 4(5):e5547. Epub 2009 May 14.